Loading
CCR4 is a chemokine receptor on skin-homing and regulatory T cells, and on the malignant cells of cutaneous T-cell lymphoma and adult T-cell leukaemia; mogamulizumab removes those cells. This dossier gathers the 1 product (1 approved), 2 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
GPCR expressed on Th2, Th17 and Treg cells and skin-homing T cells; chemotaxis to CCL17/CCL22 produced by dendritic cells and keratinocytes.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Peripheral T-cell lymphomas | 88.3% | IHC, CCR4 on tumour cells in adult T-cell leukaemia/lymphoma (91 of 103 patients) | ATLL subtype only. PTCL-NOS is heterogeneous (Ishida 2004, doi:10.1158/1078-0432.CCR-04-0371) and the MAVORIC CTCL approval did not require CCR4 testing | PMC |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved |
|---|---|
| Antibody 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
MAVORIC NCT01728805 | 3 | Positive | Previously treated mycosis fungoides or Sezary syndrome: the anti-CCR4 antibody mogamulizumab against the oral HDAC inhibitor vorinostat, with crossover allowed | Mogamulizumab improved progression-free survival over vorinostat in previously treated mycosis fungoides and Sezary syndrome; approved in August 2018. | |
| 2 | Recruiting | A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CCR4" OR ABSTRACT:"CCR4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCR4, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/ccr4.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ccr4.json. Licence CC BY-NC 4.0.